A National Push for Drug Payment Disclosures
Last week, The New York Times reported on the Obama Administration’s push to disclose payments that doctors receive from drug makers and medical device companies. And this past Saturday, The Boston Globe weighed in with an editorial in favor of this new federal disclosure plan as well. At Partners HealthCare, we support this level of transparency. The relationship between the academic medical community and the medical industry is fundamentally important for translating scientific advances into patient care improvements. However, this relationship must be managed in a way that assures and preserves the actual – and perceived – integrity of our research, education and patient-care activities.
In 2009, Partners introduced a sweeping set of recommendations to ensure the ongoing integrity of our relationship with the medical industry while earning the public’s confidence. Our policies now prohibit certain types of activities, such as participation in speakers bureaus or ghost-writing articles on behalf of the industry. These policies also impose more oversight on the outside activities of our senior institutional officials, as well as on industry-funded educational programs, to ensure that these relationships are managed appropriately. At the same time, they encourage and recognize the importance of maintaining our decades-long tradition of medical innovation through scientific partnerships with industry.
Tags: industry interactions










